Immunological characterization of glioblastoma cells for immunotherapy

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2525-2534

  Jung, Tae Young ^a   Choi, Yoo Duk ^a   Kim, Young Hee ^a   Lee, Je Jung ^a   Kim, Hyung Seok ^a   Kim, Ju Sun ^b   Kim, Sang Ki ^b   Jung, Shin ^a   Cho, Duck ^a  

^a Chonnam National University   (South Korea)

^b Kongju National University   (South Korea)

Author keywords

Characterization; Glioblastoma; Immunotherapy; Tumorassociated antigens; U251; U343 cells; U87

Indexed keywords

BIRC5 PROTEIN; CD133 ANTIGEN; CD137 ANTIGEN; CD99 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; MHC CLASS I RELATED CHAIN A; MHC CLASS I RELATED CHAIN B; TUMOR ANTIGEN; UL16 BINDING PROTEIN 1; UL16 BINDING PROTEIN 2; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; ERBB2 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BRAIN TISSUE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL ASSAY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; CYTOTOXICITY TEST; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; WESTERN BLOTTING; BIOSYNTHESIS; CHARACTERIZATION; GENE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; TUMOR CELL LINE; TUMOR-ASSOCIATED ANTIGENS; U251; U343 CELLS; U87;

CHARACTERIZATION; GLIOBLASTOMA; IMMUNOTHERAPY; TUMOR-ASSOCIATED ANTIGENS; U251; U343 CELLS; U87;

ANTIGENS, CD; CELL ADHESION MOLECULES; CELL LINE, TUMOR; GENES, MHC CLASS I; GENES, MHC CLASS II; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; KILLER CELLS, NATURAL; RECEPTOR, ERBB-2;

MLCS; MLOWN;

EID: 84881361653     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Kim YH, Jung TY, Jung S, Jang WY, Moon KS, Kim IY, Lee MC, and Lee JJ: Tumour-infiltrating T-cell subpopulations in glioblastomas. Kim YH, Jung TY, Jung S, Jang WY, Moon KS, Kim IY, Lee MC and Lee JJ: Tumour-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg 26: 21-27, 2012.
3. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM and Lieberman FS: Induction of CD8+ T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336, 2011.
4. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF and Liau LM: Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17: 1603-1615, 2011.
5. Wheeler CJ and Black KL: DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18: 509-519, 2009.
6. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y and Quillien V: Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81: 139-148, 2007.
7. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H and Jadus MR: Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13: 566-575, 2007.
8. Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW and Jadus MR: Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol 88: 65-76, 2008.
9. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G and Bottino C: NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182: 3530-3539, 2009.
10. Imai C, Iwamoto S and Campana D: Campana, Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383, 2005.
11. Cho D and Campana D: Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 29: 89-96, 2009.
12. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ and Lee DA: Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7: e30264, 2012.
13. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO Classification of Tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
14. Jang YY, Cho D, Kim SK, Shin DJ, Park MH, Lee JJ, Shin MG, Shin JH, Suh SP and Ryang DW: An improved flow cytometrybased natural killer cytotoxicity assay involving calcein AM staining of effector cells. Ann Clin Lab Sci 42: 42-49, 2012.
15. Izumoto S: Peptide vaccine. Adv Exp Med Biol 746: 166-177, 2012.
16. Yamanaka R and Kajiwara K: Dendritic cell vaccines. Adv Exp Med Biol 746: 187-200, 2012.
17. Lanier LL: Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502, 2008.
18. Cho D, Kim SK and Carson WE 3rd: NK cell-based immunotherapy for treating cancer: will it be promising? Korean J Hematol 46: 3-5, 2011.
19. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL and Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729, 1999.
20. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M and Chalupny NJ: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133, 2001.
21. Li P, Morris DL, Willcox BE, Steinle A, Spies T and Strong RK: Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2: 443-451, 2001.
22. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H and Campana D: Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16: 3901-3909, 2010.
23. Park YK, Shin DJ, Cho D, Kim SK, Lee JJ, Shin MG, Ryang DW, Lee JS, Park MH, Yoon JH and Jegal YJ: Interleukin-21 increases direct cytotoxicity and IFN-gamma production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res 32: 839-846, 2012.
24. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403, 2006.
25. Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, You QD and Guo QL: Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279: 13-21, 2009.
26. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004.
27. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 65: 6207-6219, 2005.
28. Ajeawung N and Kamnasaran D: An efficient approach to Enrich Glioma Stem Cells from Glioma Cell Lines in Culture. WebmedCentral Oncology 1(9): WMC00557, 2010.
29. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J and Quillien V: Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cellmediated killing compared with serum-cultured glioblastoma cells. Brain Pathol 22: 159-174, 2012.
30. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
31. Lindley DJ, Roth WJ, Carl SM and Knipp GT: The effects of media on pharmaceutically relevant transporters in the human HT-29 adenocarcinoma cell line: does culture media need to be controlled? J Pharm Sci 101: 1616-1630, 2012.
32. Pfeifer N, Baston-Bust DM, Hirchenhain J, Friebe-Hoffmann U, Rein DT, Krussel JS and Hess AP: Selection of the In Vitro Culture Media Influences mRNA Expression of Hedgehog Genes, Il-6, and Important Genes regarding Reactive Oxygen Species in Single Murine Preimplantation Embryos. ScientificWorldJournal 2012: 479315, 2012.
33. Roth WJ, Lindley DJ, Carl SM and Knipp GT: The effects of intralaboratory modifications to media composition and cell source on the expression of pharmaceutically relevant transporters and metabolizing genes in the Caco-2 cell line. J Pharm Sci 101: 3962-3978, 2012.
34. von Kleist S, Chany E, Burtin P, King M and Fogh J: Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst 55: 555-560, 1975.
35. Seol HJ, Chang JH, Yamamoto J, Romaqnuolo R, Suh Y, Weeks A, Aqnihotri S, Smith CA and Rutka JT: Overexpression of CD99 Increases the Migration and Invasiveness of Human Malignant Glioma Cells. Genes Cancer 3: 535-549, 2012.